Charles River and Insightec Announce Strategic Collaboration to Advance Therapeutic Development Utilizing Focused Ultrasound in Neuroscience
Neptune Flood Reaches Milestone of 200,000 Policies and $250 Million of Premium in Force
Charles River Laboratories to Present at Baird and Morgan Stanley Conferences
Magnificent 7 Miss Out, 2 Cybersecurity Stocks Stand Firm, Retailers Lag In Volatile August: Here Are The Top S&P 500 Gainers And Losers
Super Micro's Precipitous August Stock Selloff Can Be Summed up by These Stats
Charles River Laboratories International (CRL) Fell Due to a More Cautious Funding Environment
Is Wall Street Bullish or Bearish on Charles River Laboratories Stock?
Should You Investigate Charles River Laboratories International, Inc. (NYSE:CRL) At US$205?
Reasons Why You Should Bet on Charles River (CRAI) Stock Now
Zacks.com Featured Highlights Leidos, Trane, Cabot, Vertiv and Charles River
Charles River Associates (CRA) Strengthens Its Energy Practice
S&P 500 Futures Steady In Premarket Trading; United Therapeutics, Tempus AI Lead
Terumo and Charles River Demonstrate Effectiveness of CGT Manufacturing Device
Medicare's Negotiated Drug Prices Will Save Taxpayers $6 Billion in First Year, White House Says
US Drug Price Measure to Cut Costs by US$7.5b in 2026
Mizuho Securities Maintains Charles River(CRL.US) With Hold Rating
Hold Rating on Charles River Labs Amidst Pharma Restructuring and Uncertain Near-Term Earnings
CRL Announces Tru-Motion Products LLC as New Channel Partner
Express News | Charles River Laboratories International Inc : Mizuho Cuts Target Price to $210 From $235
Mizuho Adjusts Price Target on Charles River Laboratories International to $210 From $235, Maintains Neutral Rating